JPMorgan raised the firm’s price target on Grifols to $10.50 from $10 and keeps a Neutral rating on the shares. In 2024, the analyst expects the European pharma and biotech sector to continue to outperform the wider market, but only because the firm expects the quality names to carry the sector as happened in 2023. JPMorgan does not expect 2024 to be a year when the “have-nots” stage a comeback, as it continues to see a bifurcation in pharma company outlooks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRFS:
- Grifols completes cohort 1 in study of Alpha-1 15%
- Grifols price target lowered to EUR 11 from EUR 11.50 at Barclays
- GigaGen presents IND-enabling data, Phase 1 trial strategy for GIGA-564
- Is GRFS a Buy, Before Earnings?
- Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
